The Dengue Vaccine Initiative (DVI) is a consortium of organizations working to lay the groundwork for dengue vaccine introduction in endemic areas so that, once licensed, vaccines to prevent dengue will be swiftly adopted by countries most in need. DVI builds on the momentum and capabilities of the Pediatric Dengue Vaccine Initiative (PDVI) and focuses on creating an enabling environment for vaccine introduction and on maintaining a pipeline of vaccine candidates.
DVI is creating an environment for accelerated vaccine introduction by conducting evidence-based research to inform policy, both at the global level and for selected “early adopter” countries, with a particular focus on Colombia, Brazil, Viet Nam and Thailand. As a product-development partnership, DVI is focused on using the knowledge and expertise of its members to accelerate the development and distribution of a dengue vaccine.
DVI works in partnership with governments, industry and the scientific community to increase the priority given to dengue vaccines at the global level and work for a world free of dengue.